Starbucks UK reports £35.2m loss in 2024
Starbucks UK has reported a £35.2m ($44.8m) pre-tax loss for the 12 months ended 29 September 2024, a contrast to the £16.9m profit posted the previous year.
The downturn is accompanied by a 9% fall in gross profit and a 4% year-on-year decline in UK revenues to £525.6m.
The coffee giant attributed its performance to factors such as high raw material costs, reduced consumer spending and "widely discussed misperceptions" about the company's stance on the Israel-Gaza conflict.
Starbucks also noted the impact of a highly competitive branded coffee shop market in the UK, which has seen increased investment in domestic speciality coffee chains. This surge in investment has intensified the competition for Starbucks in the UK.
Despite these challenges, Starbucks ended the year with 1,240 stores - an increase of 100 net new sites.
It also expanded its company-owned UK estate by acquiring its largest UK franchisee, 23.5 Degrees, adding 113 stores.
Starbucks plans to open an additional 80 net new UK stores by the end of September 2025.
Starbucks Europe, Middle East and Africa president Duncan Moir stated: 'It has been a difficult period for the sector. We navigated significant macro-economic pressures, including inflationary headwinds, which have also had an impact on consumer confidence. Despite this, we achieved our goal of opening 100 new stores in the UK.
'We remain committed to further expanding our presence and are today announcing that we will open an additional 80 stores in the UK this year.
'We are focused on regaining momentum by strengthening and scaling how we integrate technology across the business, building on the popularity of our Starbucks Rewards programme, and further optimising our menu to ensure we continue delivering on our core offering every time.'
In March 2025, Starbucks revealed plans to expand seating options and power outlets to charge devices, seeking to become more customer-friendly and boost sales. The coffee chain is testing new store designs in the US to reverse its sales slump.
"Starbucks UK reports £35.2m loss in 2024" was originally created and published by Verdict Food Service, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies
PETACH TIKVA, Israel, June 2, 2025 /PRNewswire/ -- ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical isotope with significant potential in targeted radiotherapeutics. This partnership addresses longstanding supply challenges for Gd-160, enabling Isotopia to advance Tb-161-based therapies for prostate cancer, neuroendocrine tumors, and other malignancies. Under the agreement, ASP Isotopes will leverage its proprietary Quantum Enrichment technology to provide Isotopia with enriched Gd-160, a stable isotope essential for manufacturing Tb-161. The collaboration combines ASP Isotopes' expertise in large-scale isotope enrichment—previously demonstrated through its production of Ytterbium-176 (Yb-176)—with Isotopia's proven capabilities in commercial-scale medical isotope production. Isotopia has consistently manufactured Lutetium-177 (Lu-177) and maintained weekly Tb-161 production for its clinical trials over the past two years. Paul Mann, CEO of ASP Isotopes, emphasized the agreement's significance: "By supplying Gd-160, we are eliminating a major bottleneck in the development of Tb-161 therapies. Our investment in enrichment technology positions us to support the radiopharmaceutical industry's growing demand for stable isotopes. This partnership accelerates the path to clinical adoption of Tb-161, which could redefine cancer treatment paradigms." Dr. Eli Shalom, CEO of Isotopia, highlighted Tb-161's therapeutic advantages: "Tb-161's dual mechanism of action, including Auger electron emissions, enables precise targeting of micro-metastases while minimizing damage to healthy tissues. This partnership ensures a reliable Gd-160 supply chain, allowing us to scale production and advance our Tb-161-labeled drug candidates toward commercialization. We produce in our site in Israel and shortly the production will start in our second site in Indianapolis in the US." Tb-161's Auger electrons induce double-strand DNA breaks in cancer cells, offering potential advantages over Lu-177 and alpha-emitting isotopes. This precision aligns with the oncology field's shift toward targeted radiotherapeutics, which improve efficacy and reduce side effects. The agreement comes as global interest in radiopharmaceuticals surges, driven by their ability to deliver localized radiation therapy via tumor-seeking molecules. About ASP Isotopes Inc. ASP Isotopes Inc. specializes in advanced isotope separation technologies, including its proprietary Aerodynamic Separation Process and Quantum Enrichment, which produce stable isotopes without radioactive waste. The company's initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company has isotope enrichment facilities in Pretoria, South Africa. For more information, please visit About Isotopia Molecular Imaging Ltd. Isotopia is a global leader in medical isotope production, with facilities in Israel, Europe, and the U.S. Its integrated platform includes cyclotrons, Lu-177 and Tb-161 production sites, and sterile manufacturing capabilities. The company collaborates with researchers and clinicians to develop novel radiopharmaceuticals for diagnostics and targeted therapy. This partnership positions both companies at the forefront of the radiopharmaceutical revolution, with the potential to expand treatment options for cancer patients worldwide. Contact: eshalom@ SOURCE Isotopia

Yahoo
11 hours ago
- Yahoo
Influential economist Stanley Fischer dies
Stanley Fischer, a former top policymaker at the US Federal Reserve and the Bank of Israel whose thinking was highly influential among Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Bloomberg
16 hours ago
- Bloomberg
Summers, Bernanke Recall Fischer as Brilliant Economic Scholar
Stanley Fischer was remembered Sunday as a mentor to economic luminaries around the world. Fischer, who died Saturday at 81, was a central banker in the US and Israel. He served as vice chairman of the US Federal Reserve from 2014 to 2017 following eight years as governor of the Bank of Israel. That added to a resume that included time at the Massachusetts Institute of Technology, spells at the International Monetary Fund and World Bank, and a stint as vice chairman of New York-based Citigroup Inc.